Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price objective [...]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of “Moderate Buy” by Brokerages
